257 related articles for article (PubMed ID: 14552419)
1. Synthetic glycopeptides for the development of tumour-selective vaccines.
Kunz H
J Pept Sci; 2003 Sep; 9(9):563-73. PubMed ID: 14552419
[TBL] [Abstract][Full Text] [Related]
2. Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4.
Dziadek S; Brocke C; Kunz H
Chemistry; 2004 Sep; 10(17):4150-62. PubMed ID: 15352098
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of tumor-associated glycopeptide antigens for the development of tumor-selective vaccines.
Dziadek S; Kunz H
Chem Rec; 2004; 3(6):308-21. PubMed ID: 14991920
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
Hanisch FG; Stadie T; Bosslet K
Cancer Res; 1995 Sep; 55(18):4036-40. PubMed ID: 7545084
[TBL] [Abstract][Full Text] [Related]
5. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
7. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin.
Dziadek S; Kowalczyk D; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7624-30. PubMed ID: 16247814
[No Abstract] [Full Text] [Related]
8. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
[No Abstract] [Full Text] [Related]
9. Synthesis and structural model of an alpha(2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions.
Dziadek S; Griesinger C; Kunz H; Reinscheid UM
Chemistry; 2006 Jun; 12(19):4981-93. PubMed ID: 16642533
[TBL] [Abstract][Full Text] [Related]
10. Synthetic glycopeptides for the development of cancer vaccines.
Liakatos A; Kunz H
Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
[TBL] [Abstract][Full Text] [Related]
11. Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides.
George SK; Schwientek T; Holm B; Reis CA; Clausen H; Kihlberg J
J Am Chem Soc; 2001 Nov; 123(45):11117-25. PubMed ID: 11697954
[TBL] [Abstract][Full Text] [Related]
12. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of MUC1 glycopeptide thioesters and ligation via direct aminolysis.
Wilkinson BL; Chun CK; Payne RJ
Biopolymers; 2011; 96(2):137-46. PubMed ID: 20564042
[TBL] [Abstract][Full Text] [Related]
14. Efficient substitution reaction from cysteine to the serine residue of glycosylated polypeptide: repetitive peptide segment ligation strategy and the synthesis of glycosylated tetracontapeptide having acid labile sialyl-T(N) antigens.
Okamoto R; Souma S; Kajihara Y
J Org Chem; 2009 Mar; 74(6):2494-501. PubMed ID: 19236026
[TBL] [Abstract][Full Text] [Related]
15. Functional neoglycopeptides: synthesis and characterization of a new class of MUC1 glycoprotein models having core 2-based O-glycan and complex-type N-glycan chains.
Matsushita T; Sadamoto R; Ohyabu N; Nakata H; Fumoto M; Fujitani N; Takegawa Y; Sakamoto T; Kurogochi M; Hinou H; Shimizu H; Ito T; Naruchi K; Togame H; Takemoto H; Kondo H; Nishimura S
Biochemistry; 2009 Nov; 48(46):11117-33. PubMed ID: 19852465
[TBL] [Abstract][Full Text] [Related]
16. The (2-phenyl-2-trimethylsilyl)ethyl-(PTMSEL)-linker in the synthesis of glycopeptide partial structures of complex cell surface glycoproteins.
Wagner M; Dziadek S; Kunz H
Chemistry; 2003 Dec; 9(24):6018-30. PubMed ID: 14679514
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of tumor associated sialyl-T-glycopeptides and their immunogenicity.
Komba S; Werdelin O; Jensen T; Meldal M
J Pept Sci; 2000 Dec; 6(12):585-93. PubMed ID: 11192238
[TBL] [Abstract][Full Text] [Related]
18. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
Dziadek S; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
[No Abstract] [Full Text] [Related]
19. Multiple column synthesis of a library of T-cell stimulating Tn-antigenic glycopeptide analogues for the molecular characterization of T-cell-glycan specificity.
Frische K; Meldal M; Werdelin O; Mouritsen S; Jensen T; Galli-Stampino L; Bock K
J Pept Sci; 1996; 2(4):212-22. PubMed ID: 9231328
[TBL] [Abstract][Full Text] [Related]
20. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
